Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
基立福的子公司Biotest預計，在近7年內，其靜脈免疫球蛋白Yimmugo在美國銷售的營業收入將達到約10億美元，此前該產品已獲得FDA批准用於治療原發性免疫缺陷病。
- Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025
- Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market
- It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics
- Yimmugo will be followed by other proteins in the pipeline, including fibrinogen and trimodulin, both in late-stage development